The Manufacturers Life Insurance Company lifted its stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 100.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,978 shares of the company’s stock after acquiring an additional 14,509 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.07% of Global Blood Therapeutics worth $792,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Global Blood Therapeutics by 30.0% during the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock worth $93,114,000 after acquiring an additional 785,691 shares during the last quarter. Vanguard Group Inc. grew its stake in Global Blood Therapeutics by 15.7% during the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock worth $80,224,000 after purchasing an additional 397,271 shares during the period. State Street Corp grew its stake in Global Blood Therapeutics by 217.9% during the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after purchasing an additional 1,465,595 shares during the period. Janus Henderson Group PLC acquired a new stake in Global Blood Therapeutics during the second quarter worth approximately $26,919,000. Finally, Sectoral Asset Management Inc grew its stake in Global Blood Therapeutics by 31.0% during the second quarter. Sectoral Asset Management Inc now owns 452,781 shares of the company’s stock worth $12,384,000 after purchasing an additional 107,199 shares during the period. Institutional investors own 86.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: “The Manufacturers Life Insurance Company Has $792,000 Stake in Global Blood Therapeutics, Inc. (GBT)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/17/the-manufacturers-life-insurance-company-has-792000-stake-in-global-blood-therapeutics-inc-gbt.html.

Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at $40.05 on Friday. Global Blood Therapeutics, Inc. has a 1 year low of $13.35 and a 1 year high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same period last year, the company posted ($0.58) earnings per share. equities analysts forecast that Global Blood Therapeutics, Inc. will post -2.53 EPS for the current year.

In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the sale, the vice president now directly owns 2,684 shares in the company, valued at $93,940. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Charles J. Homcy sold 70,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares in the company, valued at $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold 91,500 shares of company stock worth $3,093,350 over the last quarter. 5.30% of the stock is currently owned by corporate insiders.

Several equities research analysts recently commented on GBT shares. Morgan Stanley reaffirmed an “overweight” rating and set a $56.00 target price (up previously from $51.00) on shares of Global Blood Therapeutics in a research note on Friday, October 6th. BidaskClub cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 14th. Needham & Company LLC set a $51.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research cut Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Finally, J P Morgan Chase & Co reissued a “buy” rating on shares of Global Blood Therapeutics in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the stock. Global Blood Therapeutics has an average rating of “Buy” and an average price target of $55.00.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.